ArticleAmerican journal of translational research2024
Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the clinical effectiveness and safety of Camrelizumab immunotherapy in patients with advanced esophageal carcinoma (aEC).
methodsA retrospective study was conducted on 142 aEC cases admitted between May 2020 to October 2022. The patients who received albumin-bound paclitaxel (ALB-bound PTX) and cis-platinum (DDP) were grouped into the control group (n=72), and the others received Camrelizumab immunotherapy in combination with ALB-bound PTX and DDP were grouped in to the research group (n=72). The clinical effectiveness, side effects (rash, nausea/vomiting, impaired liver function, leukopenia, thrombocytopenia, and alopecia), tumor marker levels (CEA, CA199, and CA125), immunoglobulin levels (IGA, IGM, and IGG), immune molecule levels (PD-1 and PD-L1), and the one-year survival rate were compared between the two groups. Furthermore, the risk factors affecting therapeutic effectiveness were identified by binary Logistic regression analysis.
resultsCompared to the control group, the research group demonstrated a higher overall response rate, fewer side effects, and greater reductions in the levels of CEA, CA199, and CA125 after treatment. IgA, IgM, and IgG levels increased significantly in both groups after treatment, with a more pronounced improvement in the research group. PD-1 and PD-L1 levels decreased significantly after treatment, especially in the research group. The one-year survival rate was higher in the research group. Furthermore, treatment modality was a risk factor affecting therapeutic effectiveness in aEC patients.
conclusionsCamrelizumab immunotherapy is highly effective in treating aEC. It can increase the one-year survival rate, and elevate the levels of immunoglobulins and immune molecules while reducing the levels of tumor markers and incidence of side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.